Pola-BR方案治疗复发/难治弥漫大B细胞淋巴瘤的真实世界研究现状  

Current Status of Real-World Studies of Pola-BR in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

作　　者：闻一格 曾瀚庆[1] 

机构地区：[1]重庆医科大学附属第二医院血液内科,重庆

出　　处：《临床医学进展》2025年第2期1535-1539,共5页Advances in Clinical Medicine

摘　　要：为方便了解Pola-BR方案在真实世界中治疗复发/难治弥漫大B细胞淋巴瘤的疗效及安全性,本文分析总结了9项回顾性真实世界研究,结果表明使用Pola-BR方案的真实世界数据虽没有GO29365试验的结果理想,但仍然是治疗R/R DLBCL的一种比较好的选择。To facilitate understanding of the efficacy and safety of the Pola-BR in the treatment of relapsed/ refractory diffuse large B-cell lymphoma in the real world, this article analyzes and summarizes nine retrospective real-world studies, and the results suggest that real-world data using the Pola-BR regimen, although not as promising as the results of the GO29365 trial, is still a better option for the treatment of R/R DLBCL.

关 键 词：维泊妥珠单抗 苯达莫司汀 利妥昔单抗 复发/难治弥漫大B细胞淋巴瘤 真实世界研究 

分 类 号：R73[医药卫生—肿瘤]